Citadel Advisors
ITOS

Citadel Advisors’s iTeos Therapeutics ITOS Stock Holding History

Citadel Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-168,100
Closed -$1.68M – 13427
2025
Q2 		$1.68M Buy
168,100
+167,200
+18,578% +$1.35M ﹤0.01% 6051
2025
Q1 		$5.37K Sell
900
-16,900
-95% -$124K ﹤0.01% 13822
2024
Q4 		$137K Sell
17,800
-14,300
-45% -$123K ﹤0.01% 11022
2024
Q3 		$328K Buy
32,100
+8,200
+34% +$125K ﹤0.01% 9146
2024
Q2 		$355K Buy
23,900
+10,800
+82% +$155K ﹤0.01% 8796
2024
Q1 		$179K Buy
13,100
+11,000
+524% +$120K ﹤0.01% 10504
2023
Q4 		$23K Sell
2,100
-17,800
-89% -$176K ﹤0.01% 12505
2023
Q3 		$218K Buy
19,900
+17,600
+765% +$225K ﹤0.01% 9737
2023
Q2 		$30.5K Buy
2,300
+2,000
+667% +$28.5K ﹤0.01% 12341
2023
Q1 		$4.08K Sell
300
-1,600
-84% -$28.7K ﹤0.01% 13985
2022
Q4 		$37.1K Sell
1,900
-8,200
-81% -$160K ﹤0.01% 12506
2022
Q3 		$192K Sell
10,100
-15,200
-60% -$350K ﹤0.01% 10445
2022
Q2 		$521K Buy
+25,300
New +$600K ﹤0.01% 8548

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's ITOS Position: Q3 2025 in Review

Citadel Advisors sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 94,256 shares — an estimated $940K sold.

Citadel Advisors first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $46.5M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Citadel Advisors reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 94,256 iTeos Therapeutics shares in Q3 2025, an estimated $940K.
  • Citadel Advisors first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
  • Citadel Advisors's iTeos Therapeutics position peaked at $46.5M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.